News from the healthcare data industry
June 02, 2023 07:05 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., today announced the launch of its tissue-naïve circulating tumor DNA (ctDNA) monitoring assay, FoundationOne®Monitor, for research use...
May 04, 2023 07:01 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., a leader in molecular profiling for cancer, today announced that it has received approval from the U.S....
Collaboration to expand access to precision medicine for members with late-stage solid tumors March 02, 2023 08:00 AM Eastern Standard Time CANTON, Mass. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Point32Health, the parent company...
FDA-approved FoundationOne®CDx will be the only tissue-based comprehensive genomic profiling test covered by UnitedHealthcare FDA-approved FoundationOne®Liquid CDxwill be covered for patients with advanced breast cancer, metastatic non-small cell lung cancer,...
Partnership will focus on developing FoundationOne®CDx as a companion diagnostic for Boehringer Ingelheim’s investigational MDM2-p53 antagonist, BI 907828 January 19, 2023 07:03 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine,...
CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 /PRNewswire/ — Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracker, Foundation Medicine’s personalized circulating tumor DNA (ctDNA) monitoring assay. FoundationOne Tracker uniquely combines Foundation Medicine’s tissue-based comprehensive genomic profiling...
Foundation Medicine’s liquid biopsy test can now be used by oncologists to identify more patients with rare mutations within their cancer for whom treatment with Rozlytrek may be appropriate January...
Innovative and interactive reporting functionality offers healthcare providers additional tools to complement integrated electronic health records and make it easier to review and act on results November 14, 2022 07:05...
September 21, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals (Nasdaq: DAWN), a...
The ongoing real-world Prospective Clinicogenomic (PCG) Study compares the clinical actionability of both tissue- and blood-based comprehensive genomic profiling to limited tissue testing in this patient population August 08, 2022...